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Endogenously produced nitric oxide synthase inhibitor, asymmetric methylarginine (ADMA) is associated with vascular
dysfunction and endothelial leakage. We studied the role of ADMA, and the enzymes metabolizing it, dimethylarginine
dimethylaminohydrolases (DDAH) in the regulation of endothelial barrier function in pulmonary macrovascular and
microvascular cells in vitro and in lungs of genetically modified heterozygous DDAHI knockout mice in vivo. We show
that ADMA increases pulmonary endothelial permeability in vitro and in in vivo and that this effect is mediated by nitric
oxide (NO) acting via protein kinase G (PKG) and independent of reactive oxygen species formation. ADMA-induced
remodeling of actin cytoskeleton and intercellular adherens junctions results from a decrease in PKG-mediated phos-
phorylation of vasodilator-stimulated phosphoprotein (VASP) and a subsequent down-regulation of Rac1 activity. The
effects of ADMA on endothelial permeability, Rac1 activation and VASP phosphorylation are prevented by overexpres-
sion of active DDAHI and DDAHII, whereas inactive DDAH mutants have no effect. These findings demonstrate for the
first time that ADMA metabolism critically determines pulmonary endothelial barrier function by modulating Rac1-
mediated remodeling of the actin cytoskeleton and intercellular junctions.
INTRODUCTION
The endothelium constitutes the inner lining of blood ves-
sels and regulates exchange of fluids, macromolecules, and
leukocytes between blood and interstitial tissues. Precise
control of endothelial barrier function strongly depends on
endothelial nitric oxide (NO) production, as both inhibition
and excessive amounts of NO can induce vascular leakage
(Predescu et al., 2005; Hatakeyama et al., 2006). Methylargin-
ines such as the guanidino-methylated arginine analogue
N(G)-mono-methyl-l-arginine (L-NMMA) or asymmetric
dimethylarginine (ADMA) are naturally occurring mole-
cules that inhibit the activity of the enzymes responsible for
NO production, nitric oxide synthases (NOS; Vallance and
Leiper, 2004). ADMA is a cardiovascular risk factor and its
plasma levels are increased in conditions associated with
endothelial dysfunction and vascular leakage such as diabe-
tes, atherosclerosis, pulmonary and systemic hypertension,
hypercholesterolemia, hyperglycemia and heart failure (Val-
lance and Leiper, 2004; Cooke, 2005). Symmetric dimethyl-
arginine (SDMA) does not act as an inhibitor of NOS (Val-
lance and Leiper, 2004). The level of methylarginines is
controlled in part by the enzymes dimethylarginine dimeth-
ylaminohydrolases I and II (DDAH I and II; Vallance and
Leiper, 2004). Analysis of methylarginine metabolism in the
cardiovascular system has identified the lung as a major
source of ADMA (Bulau et al., 2007). However, the role of
this prevailing methylarginine in vivo, in the regulation of
pulmonary endothelial barrier function is not known.
Methylarginines reduce synthesis of NO. Reduction of
NO generation in vivo induces microvessel leakage in pul-
monary circulation of eNOS/mice treated with the NOS
inhibitor L-NAME [N(G)-nitro-l-arginine methyl ester; Pre-
descu et al., 2005] and in the isolated perfused rabbit lung
after NOS inhibition (Mundy and Dorrington, 2000), but the
mechanisms are unclear. NOS inhibitors appear to have a
direct effect on endothelial barrier function in vivo (Predescu
et al., 2005), but their actions may also involve indirect,
secondary mechanisms such as increased neutrophil adhe-
sion (Rumbaut et al., 2000). In addition to inhibition of NO
production, it has been proposed that ADMA might uncou-
ple NOS leading to superoxide production (Cardounel et al.,
2005). Oxidative stress increases in many models of pulmo-
nary hypertension and both increases (van Wetering et al.,
2002) and decreases in ROS (Wojciak-Stothard et al., 2005)
can disrupt endothelial barrier function.
We have recently shown that ADMA differentially reg-
ulates the activities of the known regulators of actin dy-
namics, Rho GTPases RhoA, Rac1, and Cdc42 in PAECs
(Wojciak-Stothard et al., 2007). Rho GTPases are important in
the regulation of endothelial barrier function. Activation of
RhoA increases endothelial permeability by increasing en-
dothelial actomyosin contractility and intercellular gap for-
mation (van Nieuw Amerongen and van Hinsbergh, 2001).
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In contrast, Rac1 activity is required for the assembly, main-
tenance, and recovery of endothelial intercellular junctions
(Waschke et al., 2004; Wojciak-Stothard et al., 2005). Cdc42
has been shown to promote junction recovery after thrombin
treatment in human pulmonary arterial endothelial cells
(Kouklis et al., 2004).
Downstream effectors of NO, cAMP-activated protein ki-
nase A (PKA) and cGMP-activated protein kinase G (PKG)
may also mediate the effects of methylarginines. PKA and
PKG have been implicated in the control of endothelial
permeability but, depending on the vascular bed, their ef-
fects have been either protective or detrimental (van Nieuw
Amerongen and van Hinsbergh, 2002). Both kinases phos-
phorylate vasodilator-stimulated phosphoprotein (VASP),
which links intercellular junction proteins and integrins
with the actin cytoskeleton (Krause et al., 2003). Genetically
altered mice have indicated a crucial role of VASP for vas-
cular integrity (Furman et al., 2007) but the role of VASP
phosphorylation in control of junctional integrity remains
unclear. VASP phosphorylation by PKA was postulated to
strengthen intercellular adhesions (Comerford et al., 2002),
but others have shown that it may interfere with the assem-
bly of cortical actin cytoskeleton and decrease intercellular
adhesion (Benz et al., 2008). VASP phosphorylation by PKG
has been shown to induce reorganization of endothelial
cytoskeleton and enhance angiogenesis (Chen et al., 2008),
but its effects on endothelial barrier function are not known.
Interestingly, VASP localization and activity in endothelial
cells is closely associated with Rac1 activation and junctional
integrity (Schlegel et al., 2008).
We studied the role of ADMA metabolism in the regula-
tion of endothelial permeability in cultured primary macro-
vascular and microvascular pulmonary endothelial cells in
vitro and in mouse lungs in vivo. We also sought to eluci-
date the mechanism by which methylarginines affect the
organization of junction-associated cytoskeleton and inter-
cellular junctions in endothelial cells.
MATERIALS AND METHODS
Cell Culture
Porcine pulmonary artery endothelial cells (PAECs) were purchased from
Cell Applications (San Diego, CA) and cultured as in Wojciak-Stothard et al.
(2005, 2007). Mouse pulmonary microvascular cells (PMVECs) were isolated
from peripheral parts of the lung of DDAHI heterozygous (HT) knockout
mice, purified, and cultured as described in Wojciak-Stothard et al. (2007).
PMVECs from normal wild-type (WT) littermates were used as controls.
Heterozygous DDAHI knockout mice are described in Leiper et al. (2007).
The Use of Drugs
ADMA (100 mol/l), SDMA (100 mol/l), or L-NAME (1 mmol/l, Calbio-
chem, La Jolla, CA) were added to cell cultures for 24 h. S-nitroso-N-acetyl-d,
l-penicillamine (SNAP; 10–100 mol/l, Calbiochem); guanosine 3,5-cyclic
monophosphate, 8-bromo-, sodium salt (Br-cGMP, Na; 500 mol/l, Calbio-
chem); guanosine, 3,5-cyclic monophosphorothioate,8-(4-chlorophenyl-
thio)-, Rp-Isomer, triethylammonium (Rp-8-pCPT-cGMPS, TEA; 100 nmol/l,
Calbiochem); or the flavoprotein inhibitor diphenylene iodonium (DPI, 10
mol/l; Calbiochem) were added to untreated cells or ADMA-treated cells
1 h before the end of experiment. The Rho kinase inhibitor, Y-27632 (Calbio-
chem, 5 mol/l) was added to the cells 2 h before the end of experiment, and
superoxide dysmutase mimic, Mn(III)tetrakis(1-methyl-4-pirydyl)porphyrin
pentachloride (MnTMPyP; 50 mol/l, Calbiochem,) or gap junction inhibitor,
18-glycyrrhetinic acid (18-GA, 10 mol/l, Sigma, St. Louis, MO) were
added to the cells together with ADMA and incubated for 24 h.
Plasmids and Transfection
WT GFP-VASP, S239A GFP-VASP, and S239D GFP-VASP were prepared as
in Lindsay et al. (2007). Transfection was carried out using Amaxa Nucleo-
fector system (Ko¨ln, Germany, program U-01). The cells were seeded at the
density 3  104 cells/ml and studied 48 h after transfection.
Rho, Rac, and Cdc42 GTP-binding assays and nitrite determination were
performed as described earlier (Wojciak-Stothard et al., 2007).
Construction of Recombinant Adenoviruses
Adenoviral vectors for mutant Rho GTPases, DDAHI, DDAHII, and inactive
mutants of DDAHI and DDAHII were generated as described previously
(Wojciak-Stothard et al., 2005, 2007). Inactive DDAH mutants have a Cys249
to Ser mutation in their active site, which completely inactivates the enzyme,
but does not affect protein folding.
Transendothelial Permeability Assay In Vitro
PAECs were plated in Transwell-Clear chambers (3-m pore size, 12-mm
diameter; Costar Corning, Costar, High Wycombe, United Kingdom) at cell
density of 1  104 cells/well, and grown till confluence. The cells were left
untreated or were infected with recombinant adenoviruses to induce overex-
pression of DDAH or mutant Rho GTPases. Two hours after infection, ADMA
was added to the upper and lower chambers of Transwell dishes and incu-
bated with the cells for a further 24 h. Alternatively, PAECs were transfected
with VASP mutants, plated at cell density of 3  104 cells/well, and left for
24 h to form a monolayer. After this time, ADMA was added to transfected
cells for a further 24 h. For dextran flux measurements, FITC-dextran (mo-
lecular wt 42,000, 1 mg/ml, Sigma) was added to the upper chamber of
Transwell dishes, and samples were taken from the lower compartment after
a 1-h incubation, as previously described (Wojciak-Stothard et al., 2001, 2005).
The amount of FITC-dextran was determined with a TECAN GeNios micro-
plate reader (TECAN, Reading, United Kingdom) using an excitation wave-
length of 485 nm and emission at 510 nm.
Lung Permeability In Vivo
All experiments were carried out under a Home Office License and conducted
according to the Animal Scientific Procedures Act 1986. DDAH HT knockout
mice have been characterized elsewhere (Leiper et al., 2007).
The lungs of anesthetized (Hypnorm [fentanyl and fluanisone 0.25 ml/kg]
and midazolam 25 mg/kg ip) DDAHI HT knockout mice and WT littermate
controls (five animals per group) were flushed via a catheter inserted through
right ventricle in situ in the open chest with 5 ml PBS at a flow rate of 1.8
ml/min with a nonpulsatile pump (Masterflex model 7518-00) until it was
blood free (Zhao et al., 1999). The lungs were then perfused with 10 ml of 0.16
mg/ml Evans Blue (Sigma) in PBS and with 10 ml PBS afterward. The left
lung lobe were dissected, weighed, homogenized, and suspended in 2.5 ml
formamide for extraction overnight at room temperature. The homogenates
were then centrifuged at 12,000  g, and the concentration of Evans blue in
supernatants was quantified by dual wavelength spectrophotometric analysis
at 620 and 740 nm (Moitra et al.2007). This method corrects the specimen’s
absorbance at 620 nm for the contaminating heme pigments. The Evans blue
concentration was calculated from the standard curve with the use of the
following formula: Corrected absorbance Real absorbance at 620 [1.1649
absorbance at 740  0.004] (Moitra et al., 2007). The Evans blue concentration
read in g/ml was converted to g/g wet weight of lungs using the dilution
factor of the original homogenate.
Measurement of ROS
Confluent PAECs grown on 96-well plates were treated with various phar-
macological agents as described before. Culture medium was replaced with
prewarmed Krebs saline, pH. 7.4, with or without drugs and containing
2,7-dichlorofluorescein diacetate (DCFH-DA; 5 mol/l, Calbiochem; Woj-
ciak-Stothard et al., 2005). After a 1-h incubation, DCFH fluorescence was read
at excitation wavelength of 485 and emission 530 nm on TECAN GeNios
microplate reader. Alternatively, N-acetyl-3,7-dihydroxyphenoxasine (Am-
plex Red; 50 mol/l, Molecular Probes, Eugene, OR) and horseradish perox-
idase (1 U/ml, Sigma) were dissolved in Krebs saline and added to the cells
for 1 h, and then fluorescence was read on the microplate reader at 530-nm
excitation and 590-nm emission (Takano et al., 2002).
Immunofluorescence and localization of F-actin were analyzed as described
elsewhere (Wojciak-Stothard et al., 2007). Mouse monoclonal anti-phospho-
VASP (Ser239) antibody (Upstate Biotechnology, Lake Placid, NY) and rabbit
polyclonal anti-VASP antibody (Chemicon International, Temecula, CA) were
used at 1:100.
Determination of p-Ser239 VASP was carried out with immunoprecipita-
tion of the protein with mouse monoclonal anti-phospho-VASP (Ser239)
antibody preadsorbed on A-Sepharose beads followed by Western blotting as
in Wojciak-Stothard et al. (2007).
Statistical Analysis
All the experiments were performed in triplicate. Data are presented as
means  SD. Comparisons between two groups were carried out with two-
tailed Student’s t test. When more than conditions were being compared, a
one-way ANOVA test followed by Dunnett’s post-test was used. Statistical
significance was accepted for p  0.05.
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RESULTS
ADMA But Not SDMA Induces Cytoskeletal Remodelling,
Dispersion of Intercellular Adherens Junctions, and
Increased Endothelial Permeability in PAECs
In confluent, control PAECs F-actin and VE-cadherin were
predominantly localized in the cell periphery (Figure 1, A
and B). NOS inhibitors, ADMA (100 mol/l) and L-NAME
(1 mmol/l) increased formation of stress fibers and induced
dispersion of adherens junctions, whereas SDMA (100
mol/l) had no effect (Figure 1, C–H). Consistent with their
effects on intercellular junctions, ADMA and L-NAME, but
not SDMA significantly increased endothelial permeability
(160 20 and 180 15%, respectively, p 0.01, comparison
with controls; Figure 1I). The earliest effects of the inhibitors
were noticed after 4 h, but the maximal effects were ob-
served after 24-h incubation. The time- and dose-response
permeability changes to ADMA and L-NAME are shown in
Supplementary Figure S1. The basal rate of FITC-dextran
passage through a confluent PAEC monolayer was 70
ng  h1  mm2.
Overexpression of DDAH I and DDAHII did not affect
endothelial phenotype or permeability in basal conditions
but completely prevented the effects of ADMA (Figure 2,
A–H and Q), whereas the inactive DDAH mutants had no
significant effect (Figure 2, I–Q). As shown in Figure 2, A–H,
changes induced by DDAH were also seen in cells in which
expression of the recombinant protein was not detectable by
fluorescence. To examine whether the effect of DDAH was
passed onto the neighboring cells via diffusible factors
present in medium, we studied permeability of PAECs
grown on Transwell filters, whereas DDAH-overexpressing
cells were grown on the bottom of the same Transwell
chamber. In this system, overexpression of DDAHI and
DDAHII did not significantly affect endothelial permeability
with or without ADMA (Supplementary Figure S2A). To
check if the intercellular communication plays a role, we
cultured DDAHI-overexpressing cells in the presence of
ADMA and a gap-junction inhibitor, 18-GA. Inhibition of
gap junctions significantly attenuated the effect of DDAHI
on the ADMA-induced changes in endothelial permeability
(Supplementary Figure S2B).
The Effects of ADMA on Endothelial Cytoskeletal
Remodelling and Permeability Are Mediated by NO/PKG
Pathway and Not Changes in ROS Levels
The NO donor SNAP (10 mol/l) did not affect endothelial
phenotype in control conditions, but prevented ADMA-in-
duced effects (Figure 3, I, J, and L). However, higher con-
centrations of SNAP (100 mol/l) decreased endothelial
barrier function, suggesting that an optimal level of NO is
required (data not shown). Manipulation of PKG activity
did not have a significant effect on cell morphology or per-
meability in basal conditions, though the PKG inhibitor,
Rp-8-pCPT-cGMPS, induced a modest increase in stress fi-
ber formation (Figure 3, G and K). The PKG activator, 8-Br-
cGMP, significantly reduced the effects of ADMA on cell
morphology and permeability (Figure 3, E, F, and K). Con-
sistent with its function as NOS inhibitor, ADMA reduced
nitrite levels in culture medium from 7  1.3 to 3.5  1.5
mol/l (p  0.01), the effect having been prevented by
DDAHI and DDAHII. Changes in nitrite levels induced by
ADMA and adenoviral overexpression of DDAH are shown
in Supplementary Figure S3A, whereas changes induced by
SNAP and L-NAME are shown in Supplementary Figure S3B.
We studied ROS formation using two different, commonly
used fluorescent probes, Amplex Red and DCFH-DA. Nei-
ther probe showed an increase in ROS formation after incu-
bation of the cells with ADMA or L-NAME (Supplementary
Figure S4). Amplex Red fluorescence was increased by H2O2
and menadione, a commonly used oxidant in a dose-re-
sponse manner, showing that the probe was sensitive to
ROS generation (Supplementary Figure S4). DCFH fluores-
cence was decreased by ADMA and substantially increased
by SNAP, which suggests that this probe is not entirely
specific for superoxide (Myhre et al., 2003) and may reflect
the levels of intracellular NO (Imrich and Kobzik, 1997).
Incubation of cells with a cell-permeable mimic of superox-
ide dismutase, MnTMPyP, did not prevent the effects of
ADMA (Supplementary Figure S4), which suggests that the
effects of ADMA in cultured PAECs were independent of
ROS formation.
ADMA/NO/PKG-mediated Changes in the Activity of
Rac1 Are Responsible for Remodelling of Endothelial
Actin Cytoskeleton and Adherens Junctions and Changes
in Endothelial Permeability
To verify the individual contributions of Rho GTPases to
ADMA-induced effects, we overexpressed dominant nega-
tive and constitutively activated mutants of RhoA, Rac1, and
Cdc42 in PAECs via adenoviral gene transfer.
Dominant negative RhoA, N19RhoA reduced stress fiber
formation (Figure 4, A–C) but did not significantly affect
endothelial permeability in ADMA-treated cells (144  15%;
Figure 4G). Similarly, the inhibitor of Rho kinase, Y-27632,
reduced stress fiber formation in cells (not shown) but did
not prevent ADMA-induced endothelial leakage (140 
12%; Figure 4G). In contrast, the constitutively activated
Rac1, V12Rac1, increased the levels of cortical F-actin, inhib-
Figure 1. ADMA and L-NAME but not SDMA increase endothe-
lial permeability in vitro. (A, C, E, and G) Distribution of F-actin and
VE-cadherin (B, D, F, and H) in PAECs treated with SDMA (100
mol/l), ADMA (100 mol/l), or L-NAME (1 mmol/l) for 24 h. Bar,
10 m. (I) shows changes in endothelial permeability in PAECs
treated with the inhibitors. ** p  0.01, comparison with untreated
controls, n  5.
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ited stress fiber formation and dispersion of intercellular
junctions (Figure 4, D–F), and reduced endothelial perme-
ability to control levels in ADMA-treated cells (Figure 4G).
The dominant negative Rac1, N17Rac1, significantly in-
creased endothelial permeability (160  17%), consistent
with previous reports (Wojciak-Stothard et al., 2005). This
effect was not affected by ADMA, suggesting that inhibition
of dextran flux by N17Rac1 was maximal. Rac1 activity was
up-regulated by overexpression of DDAHI or DDAHII or by
pretreatment with SNAP and 8-Br-cGMP (Figure 4, H and I),
suggesting that NO/PKG are mediators in this regulation.
DDAH, SNAP, and 8-Br-cGMP also restored Rac1 activity to
control levels in cells treated with ADMA (Figure 4, H and
I). The dominant negative Cdc42, N17Cdc42, did not affect
endothelial permeability (Figure 4G).
p-Ser239 VASP Mediates the Effects of ADMA/DDAH on
Endothelial Permeability and Rac1 Activation
Ser239 phosphorylation of VASP correlates with barrier-
enhancing effects of PKG (Draijer et al., 1995). We found that
p-Ser239 VASP was concentrated in the junctional area in
untreated PAECs (Figure 5A), whereas in ADMA-treated
cells the staining was diffuse (Figure 5B). The levels of
p-Ser239 VASP were increased in cells overexpressing
DDAHI or DDAHII but not inactive DDAH mutants (Figure
5, C and E). We observed a substantial decrease in the levels
Figure 2. DDAHI and DDAHII but not inactive
DDAH mutants prevent ADMA-induced changes in the
distribution of F-actin (A, E, I, and M), VE-cadherin (B,
F, J, and N), and endothelial permeability (Q) in PAECs.
(C, G, K, and O) Cells labeled with expression marker
GFP; (D, H, L, and P) the corresponding composite
images where F-actin is red, VE-cadherin is green, and
GFP is blue (pseudocolors). Bar, 10 m. DDAH and
their inactive mutants were expressed via adenoviral
gene transfer, and the cells were left untreated or were
treated with 100 M ADMA. * p  0.05; ** p  0.01,
comparison with untreated controls, n  5.
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of p-Ser239 VASP in PAECs treated with ADMA, which was
prevented by active DDAHI and DDAHII (Figure 5, E and
G). A decrease in VASP phosphorylation on Ser239 was also
prevented by a 1-h incubation with an NO donor, SNAP,
and a PKG activator, 8-Br-cGMP, whereas the PKG inhibitor,
Rp-8-pCPT-cGMPS, mimicked the effects of ADMA (Figure
5, F and H).
To address the contribution of VASP phosphorylation on
Ser 239 in ADMA/DDAH-induced cytoskeleton-driven ef-
fects, we overexpressed WT GFP-VASP, the phosphomi-
metic mutant S239D GFP-VASP, and the nonphosphorylat-
able mutant S239A GFP-VASP in PAECs. WT VASP or
S239D VASP did not have a significant effect on endothelial
permeability in basal conditions, but significantly reduced
endothelial leakage caused by ADMA (Figure 6A). In con-
trast, nonphosphorylatable mutant, S239A VASP increased
basal endothelial permeability (124  13%, p  0.05, com-
parison with untreated controls) and attenuated the effects
of DDAHI on ADMA-treated cells (Figure 6A). Consistent
with VASP Thr278-phosphomimetic mutants (Blume et al.,
2007), overexpression of all our VASP mutants induced for-
mation of stress fibers in cells (Figure 6B), but only S239D
VASP, and, to a lesser extent WT VASP increased cortical
F-actin localization in the junctional area (Figure 6B, ar-
rows). Overexpression of WT VASP and S239D VASP in-
creased Rac1 activity in control PAECs (145 and 130% of
controls, respectively), whereas S239A VASP reduced Rac1
activity to 40% of control levels (Figure 6, C and E). WT
VASP and S239VASP prevented ADMA-induced reduction
in Rac1 activity, whereas S239A VASP had no effect (Figure
6, C and E).
To test wheteher Rac can affect VASP in a reciprocal
manner, we overexpressed dominant negative Rac1 (N17Rac1)
in PAECs. N17Rac1 decreased the levels of p-Ser293 VASP
in cells (Figure 7), suggesting the existence of a feedback
regulatory mechanism.
DDAHI Gene Knockout Increases Pulmonary Endothelial Per-
meability In Vivo and In Vitro and Decreases Rac1 Activity and
Ser-239 Phosphorylation of VASP. DDAHI HT knockout mice
show increased plasma and tissue levels of ADMA
(Leiper et al., 2007). We observed that vascular permeabil-
ity in lungs of DDAH knockout mice was significantly
higher than in WT mice (Figure 8). During perfusion, the
lungs of DDAHI HT knockout mice accumulated 9.6  4.3 g
Evans blue/g of wet lung weight, whereas lungs of WT
mice accumulated 4.72  1.2 g Evans blue/g of wet lung
weight (p  0.05).
Consistently, cultured pulmonary microvascular cells
from DDAH knockout mice showed an increase in basal
permeability (130  18% of control value, p  0.05) and a
significantly greater response to exogenous ADMA (Figure
9A; 210  19% in DDAH HT cells and 159  18% in WT
controls, p  0.01). Overexpression of DDAHI restored en-
dothelial barrier function in DDAHI HT cells to control
levels (Figure 9A).
The cultured DDAHI HT cells showed a decrease in nitrite
levels from 10  4 to 5.9  3 mol/l (p  0.01), which was
prevented by overexpression of DDAHI (Figure 9B). We
reported previously that cultured pulmonary microvascular
cells from DDAHI HT knockout mice show up-regulation
of RhoA activity and down-regulation of Rac1 activity
(Wojciak-Stothard et al., 2007). The cells from knockout an-
imals showed small but noticeable reduction in the activity
of Rac1–88 16% (Figure 9C) and a twofold reduction in the
levels of p-Ser239 VASP (Figure 9D). Overexpression of
DDAHI in DDAHI HT cells restored activated Rac1 and
p-Ser239 VASP to control levels (Figure 9, C and D).
DISCUSSION
These experiments elucidate for the first time that ADMA
and the enzymes metabolizing it, DDAH, regulate pulmo-
Figure 3. Activation of NO/PKG pathway prevents
the effects of ADMA, whereas its inhibition mimics the
effects of ADMA on the distribution of F-actin (A, C, E,
G, and I), VE-cadherin (B, D, F, H, and J), and endothe-
lial permeability (K) in PAECs. The cells were treated
with ADMA for 24 h, and the drugs, SNAP (10–100
mol/l), 8-Br-cGMP (500 mol/l), and Rp-8-pCPT (100
nmol/l), were added 1 h before the end of the experi-
ment, as described in Materials and Methods. * p  0.05;
** p  0.01, comparison with untreated controls. (K)
## p  0.01, comparison with ADMA-treated cells. n 
5. Bar, 10 m.
ADMA Regulates Endothelial Permeability
Vol. 20, January 1, 2009 37
nary endothelial permeability in vitro and in vivo. The ef-
fects of ADMA involve reduction in NO/cGMP levels lead-
ing to decrease in Ser239 phosphorylation and Rac1
inhibition.
Precise control of NO levels by ADMA/DDAH system is
important in the maintenance of basal endothelial junctional
integrity. Exogenous and endogenous ADMA induced en-
dothelial leakage in vitro, and its effects were reversed by
overexpression of DDAH. Conversely, DDAH deficiency in
mouse lungs compromised pulmonary endothelial barrier
function in vivo. A moderate (twofold) increase in NO pre-
vented the effects of ADMA, whereas a fourfold increase in
NO induced endothelial leakage. In agreement with our
data, others have reported that small increases in NO pro-
mote intercellular junction formation in HUVECs (Kamer-
itsch et al., 2005), whereas a substantial (three- to fourfold)
increase causes endothelial leakage (Miyawaki-Shimizu et
al., 2006), likely to result from a significant increase in nitra-
tion and nitrosylation of proteins (Predescu et al., 2005).
ROS were postulated to mediate the effects induced by
methylarginines in HEK293 cells (Cardounel et al., 2005). We
did not observe any effects of superoxide dismutase mimetic
on ADMA-induced permeability or detect changes in ROS
levels induced by ADMA in pulmonary endothelial cells,
Figure 4. Rac1 but not RhoA or Cdc42 mediates the effects of ADMA on endothelial actin cytoskeleton (A and D), VE-cadherin (B and E),
and endothelial permeability (G). (C and F) are corresponding images showing expression marker, c-myc. Cells in A–C were overexpressing
N19RhoA in the presence of ADMA, whereas cells in D–F were overexpressing V12Rac1 in the presence of ADMA. Bar, 10 m. (H) The graph
shows the effects of recombinant DDAH on Rac1 activity; (I) the graph shows the effects of SNAP, 8Br-cGMP, and Rp-8-pCPT-cGMPS on Rac1
activity in untreated and ADMA-treated PAECs. Representative examples of Western blots are shown below the graphs. * p  0.05; ** p 
0.01, comparison with untreated controls. # p 0.05; ## p 0.01, comparison with ADMA-treated cells. (G) n 6; (H and I) n 4. Adenoviral
gene transfer was used to express recombinant Rho GTPases AdV12Rac1, AdN19RhoA, and AdN17Cdc42 as well as AdDDAHI, AdDDAHII,
and inactive mutants AdDDAHIM, AdDDAHIIM.
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indicating that ROS do not play a significant role in the
ADMA/DDAH pathway in those cells.
ADMA can affect different physiological processes in en-
dothelial cells by differentially regulating the Rho GTPases,
RhoA and Rac1. In sparse endothelial cells, ADMA de-
creases the levels of cGMP, which leads to activation of
RhoA and inhibition of spontaneous cell motility (Wojciak-
Stothard et al., 2007). In confluent cells in basal conditions,
inhibition of Rac1 by ADMA leads to leaky junctions,
whereas changes in RhoA activity play a lesser role. How-
ever, when endothelial cells are challenged by thrombin,
cGMP-dependent inhibition of RhoA is barrier-protective
(Klinger et al., 2006). Although Rac1 appears more important
in control of pulmonary endothelial barrier function in basal
conditions, a role of RhoA cannot be completely excluded as
Rac1 can regulate the activity of RhoA (Leeuwen et al., 1997;
Alberts et al., 2005).
We identified NO/PKG as downstream mediators of
ADMA/DDAH. Changes in PKG activity induced corre-
sponding changes in the activity of Rac1. A role of PKG in
the regulation of Rac1 was suggested in HEK-293, where
8-Br-cGMP induced a transient activation of Rac1 with ki-
netics similar to p38 MAPK phosphorylation (Hou et al.,
2004). As Rac1 is not a substrate for PKG, an indirect acti-
vation mechanism must operate in cells that may involve
modification of exchange factors for Rac1 or regulation of
their association with scaffolding proteins (Hou et al., 2004).
Here we verified the role of VASP as a potential regulator
of Rac1 activity in ADMA-mediated effects. VASP associates
with adherens (Vasioukhin and Fuchs, 2001) and tight junc-
tions (Comerford et al., 2002). Consistently, mice lacking
proteins of the VASP family die from edema formation due
to defective vascular barrier function (Furman et al., 2007).
VASP-deficient endothelial cells show increased permeabil-
ity and reduced Rac1 activity in basal conditions (Schlegel et
al., 2008) and are more susceptible to conditions of impaired
barrier function in vitro and in vivo (Benz et al., 2008).
Changes in phosphorylation of VASP by PKA or PKG ac-
company changes in endothelial junctional integrity (Draijer
et al., 1995; Comerford et al., 2002; Benz et al., 2008). The
underlying mechanism is less understood and could involve
altered interactions with the tight junction protein ZO-1
(Comerford et al., 2002) and II spectrin (Benz et al., 2008)
that are dependent on PKA-mediated Ser157 phosphoryla-
tion or impaired binding to F-actin after PKG-driven Ser239
phosphorylation. We observed that ADMA decreased phos-
phorylation of VASP on Ser239 and initiated translocation of
the protein to the cytoplasm away from endothelial junc-
tions, a change concomitant with inhibition of Rac1 and
increase in endothelial permeability that was prevented by
overexpression of DDAH. Overexpression of DDAH did not
alter electrophoretic mobility of VASP in PAECs, indicating
that Ser157 phosphorylation (that induces an electrophoretic
shift from 46 to 50 kDa) was not affected by ADMA. In
agreement with our data, PKG was shown to induce VASP
phosphorylation on Ser239 but not on Ser157 in bovine
aortic endothelial cells treated with atrial natriuretic peptide
(ANP; Chen et al., 2008).
We used mutants of Ser239 VASP to directly verify the
involvement of this phosphorylation site in control of endo-
Figure 5. Distribution of p-Ser239 VASP in untreated
cells (A), cells treated with ADMA (B), and cells over-
expressing DDAHI (C). (D) A corresponding image
showing expression marker, GFP. Bar, 10 m. (E)
Changes in the levels of p-Ser239 VASP in control and
ADMA-treated cells, as well as cells overexpressing
DDAH and their inactive mutants; n  4. * p  0.05,
** p  0.01, comparison with untreated controls; #p 
0.05, ## p  0.01, comparison with ADMA-treated cells.
Western blots in G and H show levels of p-Ser239 VASP
as well as total VASP in cells.
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thelial permeability. Phosphomimetic mutant of VASP in-
creased Rac1 activity and enhanced endothelial barrier func-
tion in untreated and ADMA-treated PAECs, whereas the
nonphosphorylatable mutant had the opposite effect. VASP
causes polymerization and bundling of actin filaments, lead-
ing to stress fiber formation and cell membrane ruffling
(Krause et al., 2003). Ser239 phosphorylation of VASP did
not affect stress fiber formation in PAECs, but increased the
levels of junction-associated F-actin, thought to strengthen
intercellular adhesion, in a manner similar to activated Rac1
(Schlegel et al., 2008). To a lesser extent, WT VASP also
induced Rac1 activation and accumulation of peripheral
F-actin, possibly resulting from Ser239 phosphorylation of
the overexpressed protein.
The precise regulatory mechanisms between VASP and
Rac1 and the role of VASP phosphorylation by PKA and
PKG in control of endothelial barrier function under differ-
ent conditions will require further studies. Though VASP
was shown to act upstream of Rac1, the feedback regulatory
mechanism may also exist. We observed that inhibition of
Rac1 reduces the levels of Ser239-phosphorylated VASP in
PAECs. Rac1 was also shown to increase junctional localiza-
tion of VASP in immortalized mouse myocardial endothelial
microvascular cells (MyEnd; Waschke et al., 2006).
Both exogenous and endogenous ADMA induced endo-
thelial dysfunction. Although the dose of exogenous ADMA
(100 mol/l) was relatively high, the change in ADMA
levels caused by heterozygous DDAHI gene deletion led to
an increase in the plasma concentration of ADMA 0.5–0.7
mol/l, similar to that reported in patients with multiple
cardiovascular risk factors (Leiper et al., 2007). It is possible
that lower doses of ADMA are required in chronic exposure
to the inhibitor as mechanisms for the acute and chronic
Figure 6. Ser239 phosphorylation of VASP is
required for the effects of DDAH on ADMA-
treated cells. PAECs expressing WT GFP-
VASP, the nonphosphorylatable mutant of
VASP (S239A GFP-VASP), or the phosphomi-
metic mutant of VASP (S239D GFP-VASP)
were left untreated, were treated with ADMA,
or were overexpressed DDAHI. (A) Effects of
VASP mutants on FITC-dextran flux in PAECs;
n  5. * p  0.05, ** p  0.01, comparison with
untreated controls; # p  0.05, ## p  0.01,
comparison with ADMA-treated cells. (B)
The effects of VASP mutants on F-actin and
VE-cadherin in recently confluent cells, as
indicated. Bar, 10 m. (C) Changes in Rac1
activity in PAECs overexpressing VASP mu-
tants, whereas corresponding Western blots
are shown in D. (E) Equal expression of
VASP-GFP mutants in PAECs is shown.
Figure 7. Rac1 inhibition decreases the levels of p-Ser239 VASP.
VASP phosphorylation was studied in untreated PAECs and PAECs
overexpressing N17Rac1. n  4. ** p  0.01.
Figure 8. DDAHI deficiency induces endothelial leakage in mouse
lungs in vivo. The lungs of DDAHI heterozygous (HT) knockout
mice and their wild-type littermates (WT) were perfused free of
blood in situ with Evans Blue in PBS. The accumulation of the dye
in the lung was quantified by dual wavelength spectrophotometric
analysis at 620 and 740 nm (Moitra et al., 2007). * p  0.05.
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exposure to ADMA are different (Suda et al., 2004). Another
possibility is that local changes in ADMA concentrations in
cells and tissues are higher than estimated. Plasma levels of
ADMA vary from 0.2–1 mol/l, but tissue levels may be
much higher reaching 15 mol/l (Cardounel et al., 2005). We
have recently reported a localized accumulation of DDAH at
the leading edge that correlated with the motile activity of
endothelial cells (Wojciak-Stothard et al., 2007). The extent
and significance of changes in ADMA concentration deter-
mined by local expression of DDAH remain to be estab-
lished. ADMA metabolism is important in the regulation of
basal endothelial permeability in vitro and in perfused lungs
in vivo, but DDAHI knockout HT mice do not appear edem-
atous (Leiper et al., 2007). Interestingly, eNOS/mice also
remain asymptomatic despite their leaky interendothelial
junctions, suggesting the existence of a compensatory mech-
anism that prevents edema formation (Predescu et al., 2005).
The barrier-protective effects of DDAH required intact
gap junctions. Formation of gap junctions is NO/cGMP-
dependent (Bazzoni and Dejana, 2004). Gap junction pro-
teins facilitate the assembly of adherens and tight junctions
(Nagasawa et al., 2006) and mediate exchange of secondary
signaling mediators between cells in the lung capillary bed
(Parthasarathi et al., 2006). The role of gap junctions in the
effects of DDAH will require further studies.
In conclusion, we show that ADMA and DDAH regulate
pulmonary endothelial permeability in an NO/PKG-depen-
dent manner. ADMA decreases the levels of Ser239-phos-
phorylated VASP, leading to inhibition of Rac1 and subse-
quent remodeling of the endothelial actin cytoskeleton and
intercellular adherens junctions. These observations suggest
that genetic or environmental factors that lead to decreased
methylarginine metabolism have the potential to decrease
pulmonary endothelial barrier function. Conversely, inter-
ventions that activate methylarginine metabolism might
have therapeutic utility in a range of cardiovascular disease
states including diabetes, atherosclerosis, pulmonary and
systemic hypertension, and heart failure.
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